glp 1 receptor agonists beyond their pancreatic effects Understanding GLP-1 and impact on drug discovery GLP-1 Receptor Agonists as Treatments

& Ma, G

While prescription GLP-1 medications can be effective, they are not without risks

In 2013, Gipg013, a GIP receptor immunoglobin G antibody, was presented

Studies suggest GLP-1 receptor agonists may slow kidney function decline, potentially through anti-inflammatory mechanisms alongside improved glycaemic control and blood pressure reduction

As these medications become more widely used, it is essential to monitor their usage trends and to understand who is using them

In the first case, hepatic steatosis presents without indication of inflammation, while in NASH hepatic steatosis is connected to lobular inflammation and apoptosis that may lead to fibrosis and cirrhosis [1] (Figure 1)